Search This Blog

Saturday, June 1, 2013

GSK announces late-stage clinical data for VOTRIENT® (pazopanib) following chemotherapy in women with advanced epithelial ovarian cancer | 2013 | Press releases | Media | GlaxoSmithKline

GSK announces late-stage clinical data for VOTRIENT® (pazopanib) following chemotherapy in women with advanced epithelial ovarian cancer | 2013 | Press releases | Media | GlaxoSmithKline

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.